HDAC4/HDAC5/HDAC9 antibody

Catalog No. ABIN7138137

The Rabbit Polyclonal anti-HDAC4/HDAC5/HDAC9 antibody has been validated for WB, IHC, IF and ELISA. It is suitable to detect HDAC4/HDAC5/HDAC9 in samples from Human.

Quick Overview for HDAC4/HDAC5/HDAC9 antibody (ABIN7138137)

Target: HDAC4/HDAC5/HDAC9 (HDAC4,HDAC5,HDAC9)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HDAC4/HDAC5/HDAC9 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA

Product Details anti-HDAC4/HDAC5/HDAC9 Antibody

Cross-Reactivity: Human, Mouse

Purification: Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Immunogen: Peptide sequence around aa.244~248/257~261/218~222 (T-A-S-E-P) derived from Human HDAC4/HDAC5/HDAC9.

Isotype: IgG

Application Details

Application Notes: WB:1:500-1:1000, IHC:1:50-1:200, IF:1:100-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for HDAC4/HDAC5/HDAC9

Target: HDAC4/HDAC5/HDAC9 (HDAC4,HDAC5,HDAC9)

Alternative Name: HDAC4/HDAC5/HDAC9

Background:

Background:

Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D.

Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.
Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.

Aliases: HD4/HD5/HD9

UniProt: P56524, Q9UQL6, Q9UKV0